Product
From drop to score in 90 seconds
We are developing a test that uses Raman spectroscopy and machine learning to look for signs of cancer in serum: one reader, one single-use cartridge, a score during the appointment.
The Serox reader
A working prototype, drop to score on real hardware: the reader, its touchscreen and the single-use cartridge. For demonstration only; not available for sale.
How it works
- 01
A small sample
A few microlitres of serum are all the test needs.
- 02
One drop, one cartridge
A drop of serum (blood with the cells removed) dries on a single-use, QR-tracked cartridge. The urine test runs on the same box.
- 03
A laser reads it
The scattered light carries a molecular fingerprint of the sample, in one reading.
- 04
A score in about 90 seconds
Machine learning turns the fingerprint into a cancer risk score, designed to support the clinician's decision alongside standard guidelines.
The destination: one box in every clinic and a model for each cancer.
- Easier A drop of serum as the first step, before a camera or a biospy needle.
- Faster A score in about 90 seconds, during the appointment.
- Cheaper Designed around one reader and a low-cost, single-use cartridge per test.
The method
We bring together photonics and machine learning
Serum contains metabolites that provide multiple biomarkers of disease within their metabolic 'soup'.
The spectrometer obtains the aggregated response from the ensemble of biomarkers contained in this metabolic soup.
Raman spectroscopy has been shown to allow discrimination between diseased and non-diseased samples.
The response of all metabolites is aggregated. Serox uses machine learning to isolate the target signals and categorise the output.
The resulting model, embodied in software, is designed to help clinicians tell diseased from non-diseased samples. Its clinical performance is being evaluated in studies.
In future, several tests could run on a single sample, with the cartridge and model optimized for each target disease.
One instrument, built for many cancers.
Our product road map
Each new cancer test is designed to run on the same reader and cartridge with its own model and clinical study. Bladder comes first, then prostate in the PSA grey zone; kidney would complete the urology set, and pancreatic is in research with the University of Oxford.
- One box
- 01 Bladder Cancer
- 02 Prostate Cancer
- 03 Kidney Cancer
- 04 Pancreatic Cancer
- 05 Primary-care Panel